2 recruiting, 1 completed. 2 Phase 1, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow STX-478: new trials by email Literature Review of STX-478 trials Research Report on STX-478
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of LY4064809 in Healthy Adult Participants LY4064809 Test Formulation, LY4064809 Reference Formulation - Healthy Participants | Phase 1 | Completed | Eli Lilly and Company | 24 | 2026-01-12 | 2026-04-20 |
| A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) LY4064809, Placebo, Ribociclib - Breast Neoplasms, Neoplasm Metastasis | Phase 3 | Recruiting | Eli Lilly and Company | 800 | 2025-12-22 | 2026-10-08 |
| First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors STX-478, Fulvestrant, Ribociclib - Breast Cancer, Solid Tumors, Adult | Phase 1 / Phase 2 | Recruiting | Eli Lilly and Company | 880 | 2023-04-17 | 2026-07-07 |
Breast Neoplasms (2) · Breast Diseases (1) · Endometrial Neoplasms (1) · Head and Neck Neoplasms (1) · Hereditary Sensory and Autonomic Neuropathies (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Neoplasms by Site (1) · Ovarian Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1) · Uterine Cervical Neoplasms (1)
United States (3) · Belgium (2) · France (2) · Germany (2) · Ireland (2) · Italy (2) · Japan (2) · Spain (2) · Argentina (1) · Australia (1) · Brazil (1) · Canada (1) · China (1) · Greece (1) · Netherlands (1)
2023 (1), 2025 (1)